Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind Placebo Controlled Study to Evaluate the Effects of Bexagliflozin on Hemoglobin A1c in Patients With Type 2 Diabetes and Increased Risk of Cardiovascular Adverse Events

NCT02558296 is registered in ClinicalTrials.gov with Theracos as lead sponsor.

NCT NCT02558296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02558296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind Placebo Controlled Study to Evaluate the Effects of Bexagliflozin on Hemoglobin A1c in Patients With Type 2 Diabetes and Increased Risk of Cardiovascular Adverse Events
Lead sponsor
Theracos
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2015
Completion date
October 23, 2019
Enrollment
1,700 (actual)
Sites
157

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus